After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to be fruitful, as demonstrated through its Keynote-B96 trial in ovarian ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.

USCIS clarified that existing visa holders, including F-1, L-1, and H-1B, won’t have to pay the new $100,000 fee for changing status or renewing H-1B. In what could be a big relief for existing US ...

There may be a constitutional challenge to the government's teen social media ban, due to its impact on the right to political communication. Legal experts say a constitutional fight over the ban ...

Does anyone believe in college education anymore? Republicans certainly don’t—a mere 19 percent of them expressed “a great deal” or “quite a lot” of confidence in higher education in a Gallup poll ...